Group 1: Financial Performance and Strategy - The company has raised 339 million CNY through its IPO, with no current plans for additional financing or mergers [3] - The asset-liability ratio is reported at 17.64%, attributed to strong operational performance and accumulated cash reserves [3] - In 2023, the company achieved a revenue growth of 25.05% in its CMC and CMO business despite a slight decline in gross margin by 11.8% [6][7] Group 2: Research and Development - The company plans to increase R&D expenditures in 2024, exceeding the 2023 levels due to sufficient funding post-IPO [6] - Ongoing projects include the development of a high-end drug formulation R&D and production base in Nanjing, currently in the foundation engineering phase [4] Group 3: Product Development and Market Expansion - The company is actively working on the clinical data for the Oseltamivir oral disintegrating tablet, which has been formally accepted by the regulatory authority [5] - Future growth strategies include product innovation, market expansion, and international development [6] Group 4: Subsidiary Performance - The subsidiary, Beijing Xinghao Yingsheng Pharmaceutical Co., Ltd., reported a revenue of 34.68 million CNY in 2023, but remains in a loss position due to production capacity constraints [7] Group 5: Stock Price Stability Measures - The company has implemented two rounds of stock buybacks, totaling 2,187,763 shares, using approximately 22.64 million CNY [8] - The company and its major stakeholders are committed to maintaining stock price stability through potential buybacks and share purchases when conditions are favorable [9]
星昊医药(430017) - 投资者关系活动记录表